Résumé
Background: 2'-deoxycytidine [Dcyd] is one of four major nucleosides found in the different normal body fluids due to dissolution of dead cells, and is increase in the presence of malignancy. Previous studies proved that it can be used as a marker for bladder cancer and acute lymphoblastic leukemia. The aim of this study is to assess 2'Dcyd as a possible biological marker in hepatocellular carcinoma [HCC]
Methods: four groups were evaluated for the level 2'-Dcyd as well as alpha-fetoprotein [AFP]; a control group [n = 20], 20 cases of chronic liver diseases [CLD], 20 cases of hepatitis C [HCV] 60 cases of HCC
Results: in the patients with HCC, 2'-Dcyd serum level was 8-fold higher than normal level. It was 3-fold higher in HCV group. A mild increase was noted in patients with chronic liver diseases. Levels >/= 0.14 of 2'-Dcyd had a sensitivity of 93% and specificity of 90% for diagnosis of HCC. It also recorded a sensitivity and specificity of 90% for diagnosis of HCV
Conclusions: for diagnosis of HCC, 2'-Dcyd is no better than AFP, as it is elevated in viral hepatitis C. A combination of AFP and 2'-Dcyd could provide broader information in diagnosis and treatment decision